Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on December 22, 2021. The report discloses developments regarding the Company's oral and intranasal/pulmonary SARS-CoV-2 main protease inhibitors program. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol "COCP".
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a regulatory disclosure rather than financial performance data.
Material Changes
The material event reported is the issuance of a press release on December 22, 2021, detailing progress in the Company's SARS-CoV-2 main protease inhibitors program. No financial comparisons to prior periods are included in this document.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of program developments referenced in the attached press release (Exhibit 99.1). The filing explicitly states that the information in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings. No specific financial guidance or risk factors are detailed within the body of this 8-K.
Key Facts for Investor Verification
- Verify the specific clinical or development milestones announced in the press release dated December 22, 2021 (Exhibit 99.1).
- Confirm the current status of the oral and intranasal/pulmonary SARS-CoV-2 main protease inhibitors program.
- Note that James Martin serves as both Chief Financial Officer and Co-Interim Chief Executive Officer.
- Review the attached press release for details not included in the 8-K summary text.